Business Description
Oncotelic Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US6283411097
Total Employee Number:
13Description
Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer. OT-101 is its flagship immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under the pipeline are Artemisinin, CA4P, AL-101, and Oxi4503.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Equity-to-Asset | 0.67 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | 0.04 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 269.6 | |||||
3-Year EPS without NRI Growth Rate | 12.6 | |||||
3-Year Book Growth Rate | 128.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 51.92 | |||||
9-Day RSI | 49.62 | |||||
14-Day RSI | 47.88 | |||||
3-1 Month Momentum % | 17.38 | |||||
6-1 Month Momentum % | -43.13 | |||||
12-1 Month Momentum % | -19.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.1 | |||||
Shareholder Yield % | -5.42 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | 224.32 | |||||
ROA % | 142.41 | |||||
ROIC % | -2.61 | |||||
3-Year ROIIC % | 0.95 | |||||
ROCE % | 232.61 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 0.07 | |||||
PB Ratio | 0.07 | |||||
Price-to-Tangible-Book | 0.07 | |||||
EV-to-EBIT | 0.08 | |||||
EV-to-EBITDA | 0.08 | |||||
EV-to-Forward-Revenue | 34.19 | |||||
EV-to-FCF | -19.49 | |||||
Price-to-Projected-FCF | 0.09 | |||||
Earnings Yield (Greenblatt) % | 1250 | |||||
FCF Yield % | -9.06 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:OTLC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Oncotelic Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | 0.566 | ||
| Beta | -0.7171 | ||
| 3-Year Sharpe Ratio | 0.55 | ||
| 3-Year Sortino Ratio | 1.11 | ||
| Volatility % | 99.97 | ||
| 14-Day RSI | 47.88 | ||
| 14-Day ATR ($) | 0.005108 | ||
| 20-Day SMA ($) | 0.03832 | ||
| 12-1 Month Momentum % | -19.3 | ||
| 52-Week Range ($) | 0.015 - 0.11 | ||
| Shares Outstanding (Mil) | 443.62 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Oncotelic Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Oncotelic Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-17 | In 107 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 11 days | ||
| General meeting for 2025 | 2026-08-03 | In 1 day | ||
| First quarter earnings results for 2026 | 2026-05-14 | 0.04 (+5.73%) | ||
| Annual report for 2025 | 2026-04-15 | 0.04 (-9.50%) | ||
| Fourth quarter earnings results for 2025 | 2026-04-15 | 0.04 (-9.50%) | ||
| Third quarter earnings results for 2025 | 2025-11-17 | 0.09 (+2.58%) | ||
| Second quarter earnings results for 2025 | 2025-08-13 | 0.04 (+16.61%) | ||
| First quarter earnings results for 2025 | 2025-05-15 | 0.06 (+6.95%) | ||
| Fourth quarter earnings results for 2024 | 2025-04-16 | 0.05 (-9.68%) |
Show
Entries
Oncotelic Therapeutics Inc Frequently Asked Questions
What is Oncotelic Therapeutics Inc(OTLC)'s stock price today?
The current price of OTLC is $0.04. The 52 week high of OTLC is $0.11 and 52 week low is $0.02.
When is next earnings date of Oncotelic Therapeutics Inc(OTLC)?
The next earnings date of Oncotelic Therapeutics Inc(OTLC) is 2026-08-13 Est..
Does Oncotelic Therapeutics Inc(OTLC) pay dividends? If so, how much?
Oncotelic Therapeutics Inc(OTLC) does not pay dividend.
Guru Commentaries on OTCPK:OTLC
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Stonegate Capital Partners Initiates Coverage on Mateon Therapeutics, Inc. | 2019-04-11 |
Articles on Oncotelic Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers